Engineered bridge protein with dual affinity for bone morphogenetic protein-2 and collagen enhances bone regeneration for spinal fusion.

Science Advances
Priscilla S BriquezJeffrey A Hubbell

Abstract

The revolutionizing efficacy of recombinant human bone morphogenetic protein (rhBMP-2) for clinical spinal fusion is hindered by safety issues associated with the high dose required. However, it continues to be widely used, for example, in InFUSE Bone Graft (Medtronic). Here, we developed a translational protein engineering-based approach to reduce the dose and thereby improve the safety of rhBMP-2 delivered in a collagen sponge, as in InFUSE Bone Graft. We engineered a bridge protein with high affinity for rhBMP-2 and collagen that can be simply added to the product's formulation, demonstrating improved efficacy at low dose of rhBMP-2 in two mouse models of bone regeneration, including a newly developed spinal fusion model. Moreover, the bridge protein can control the retention of rhBMP-2 from endogenous collagenous extracellular matrix of tissue. Our approach may be generalizable to other growth factors and collagen-based materials, for use in many other applications in regenerative medicine.

References

Sep 24, 2002·Journal of Cell Science·Roumen Pankov, Kenneth M Yamada
Apr 22, 2003·Nature Biotechnology·Matthias P LutolfJeffrey A Hubbell
Feb 11, 2009·Archives of Internal Medicine·Janet K FreburgerTimothy S Carey
Jul 7, 2011·The Spine Journal : Official Journal of the North American Spine Society·Eugene J CarrageeBradley K Weiner
Jan 25, 2013·Journal of Orthopaedic Surgery and Research·Justin BobynAaron Schindeler
Mar 15, 2013·Proceedings of the National Academy of Sciences of the United States of America·Mikaël M MartinoJeffrey A Hubbell
Jul 24, 2013·Surgical Neurology International·Nancy E Epstein
Feb 15, 2015·Experimental Gerontology·Lyndon F CharlesLiisa T Kuhn
Apr 22, 2015·Advanced Drug Delivery Reviews·Mikaël M MartinoJeffrey A Hubbell
Aug 6, 2015·Advances in Wound Care·Priscilla S BriquezMikaël M Martino
Feb 10, 2016·Tissue Engineering. Part B, Reviews·Aaron W JamesChia Soo
Jan 20, 2017·Sub-cellular Biochemistry·John W Weisel, Rustem I Litvinov
Mar 6, 2015·Materials·Lindsay S Karfeld-SulzerFranz E Weber
May 15, 2018·Tissue Engineering. Part C, Methods·Maurits G L OlthofLichun Lu
Mar 9, 2019·Rheumatology International·Francis FatoyeIsaac Odeyemi
Mar 18, 2020·Scientific Reports·Kunihiko HashimotoMasaru Ishii
Jul 17, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Deyin KongGuimei Lin

❮ Previous
Next ❯

Software Mentioned

Prism
ImageJ
Fiji
GraphPad
InFUSE

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.